These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18813198)

  • 1. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
    Cartwright T; Richards DA; Boehm KA
    Cancer Control; 2008 Oct; 15(4):308-13. PubMed ID: 18813198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New directions in the management of advanced pancreatic cancer: a review.
    Rocha-Lima CM
    Anticancer Drugs; 2008 Jun; 19(5):435-46. PubMed ID: 18418211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent updates on the role of chemotherapy in pancreatic cancer.
    Burris HA
    Semin Oncol; 2005 Aug; 32(4 Suppl 6):S1-3. PubMed ID: 16143160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular therapy of pancreatic cancer.
    Plentz RR; Manns MP; Greten TF
    Minerva Endocrinol; 2010 Mar; 35(1):27-33. PubMed ID: 20386525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palliative chemotherapy for pancreatic malignancies.
    Mehta SP
    Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer: an update.
    Kindler HL
    Curr Oncol Rep; 2007 May; 9(3):170-6. PubMed ID: 17430687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced pancreatic cancer.
    Ducreux M; Boige V; Malka D
    Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for pancreatic cancer.
    Ko AH; Tempero MA
    Semin Radiat Oncol; 2005 Oct; 15(4):245-53. PubMed ID: 16183478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
    Li J; Saif MW
    JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
    de Jager J; Stebbing J
    Future Oncol; 2006 Apr; 2(2):161-3. PubMed ID: 16563084
    [No Abstract]   [Full Text] [Related]  

  • 13. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Oberstein PE; Saif MW
    JOP; 2011 Mar; 12(2):96-100. PubMed ID: 21386629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic pancreatic cancer response to treatment with cetuximab and gemcitabine plus capecitabine: a case report and review of the literature.
    Li M; Jiang M; Yan X; Wang F; Luo F
    Tumori; 2010; 96(5):764-7. PubMed ID: 21302625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving treatment of pancreatic cancer.
    Philip PA
    Lancet Oncol; 2008 Jan; 9(1):7-8. PubMed ID: 18177814
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
    Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel advances in pancreatic cancer treatment.
    Vulfovich M; Rocha-Lima C
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):993-1002. PubMed ID: 18533808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
    Zafar SF; El-Rayes BF
    Am J Clin Oncol; 2014 Apr; 37(2):194-200. PubMed ID: 22643564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.